A prevalent liver condition called non-alcoholic fatty liver disease (NAFLD) may progress into non-alcoholic steatohepatitis (NASH) and cause life-threatening complications like cirrhosis and liver cancer. The development and progression of NAFLD has been linked to the make-up and functioning of the gut microflora. This article reviews the clinical studies reported to investigate the connection between changes in the gut microbiota and metabolic markers in NAFLD patients. According to the study findings, dysbiosis of the gut microflora were observed in NAFLD patients, which are manifested by variations in the proportions of particular bacterial species. These changes are linked to fibrosis, liver inflammation, and metabolic abnormalities. The article also discusses various treatments targeting the gut microbiota, including dietary modifications, exercise, prebiotics, probiotics, synbiotics, antibiotics, and fecal microbiota transplantation. These therapies are intended to enhance NAFLD outcomes and reestablish the healthy gut microflora. While some studies have shown promising results, further research is needed to establish the optimal approaches, long-term safety, and efficacy of these treatments for NAFLD.

中文翻译：

---

非酒精性脂肪肝与肠道菌群的相关性：临床报告和治疗方案

一种称为非酒精性脂肪肝病 (NAFLD) 的常见肝脏疾病可能会发展为非酒精性脂肪性肝炎 (NASH)，并导致肝硬化和肝癌等危及生命的并发症。 NAFLD 的发生和进展与肠道菌群的组成和功能有关。本文回顾了调查 NAFLD 患者肠道微生物群变化与代谢标志物之间关系的临床研究。根据研究结果，NAFLD 患者肠道菌群失调，表现为特定细菌种类比例的变化。这些变化与纤维化、肝脏炎症和代谢异常有关。文章还讨论了针对肠道微生物群的各种治疗方法，包括饮食调整、运动、益生元、益生菌、合生元、抗生素和粪便微生物群移植。这些疗法旨在增强 NAFLD 的治疗效果并重建健康的肠道微生物群。虽然一些研究显示出有希望的结果，但仍需要进一步研究来确定 NAFLD 治疗的最佳方法、长期安全性和有效性。